Panakes Partners

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's flagship product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system, aiming to significantly reduce the suffering of patients affected by this condition, which impacts approximately 10% of the global adult population. Neuromod's patented technology is also being evaluated for other neurological disorders, with a commitment to empowering patients and integrating treatments seamlessly into modern lifestyles.

Relief is a company that specializes in developing innovative medical devices aimed at treating urinary incontinence, particularly through the use of a unisex endo-urethral sphincter. This minimally invasive, magnetic device is designed for easy insertion and removal in an outpatient setting, making it accessible for patients. It effectively restores urinary control, even in those with severe forms of stress urinary incontinence. By offering a solution that is both invisible and user-friendly, Relief provides patients with a fast and effective treatment option that is also cost-efficient.

Approxima is an early-stage MedTech startup focused on developing a percutaneous method for tricuspid valve replacement. The company is working on a minimally invasive system designed to treat patients with tricuspid valve regurgitation by reshaping the right ventricle to counteract right heart dilation. This innovative approach enables medical professionals to implant the device using minimally invasive procedures guided by imaging techniques while the heart is still beating. Currently, Approxima is demonstrating in vivo safety, efficacy, and feasibility through preclinical trials.

Endovascular Engineering is a preclinical stage company focused on developing innovative mechanical thrombectomy solutions aimed at addressing peripheral vascular conditions. The company specializes in creating and implementing advanced clot removal technologies specifically designed for venous thromboembolism, which includes treatment for significant health issues such as pulmonary embolism and deep vein thrombosis. By equipping healthcare professionals with effective medical tools, Endovascular Engineering aims to enhance the management of these critical conditions and improve patient outcomes.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.

Alesi Surgical Ltd. specializes in the development and commercialization of laparoscopic surgical smoke handling systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2009 and based in Cardiff, United Kingdom, the company emerged as a spin-out from the Welsh Institute for Minimal Access Therapy, benefiting from direct access to experienced surgeons and surgical trainers. Alesi Surgical's innovative products are designed to be portable and applicable in both laparoscopic and robot-assisted surgeries. Utilizing electrostatic precipitation technology, these tools effectively eliminate surgical smoke, ensuring a clear visual field during procedures. Alesi Surgical distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia.

CorFlow Therapeutics is a medtech startup focused on developing innovative technologies for the diagnosis and treatment of microvascular obstructions (MVO) in patients experiencing severe heart attacks. The company has created a controlled flow infusion system that measures the degree of MVO through a proprietary concept known as dynamic microvascular resistance. This system provides interventional cardiologists with critical data that can be compared to post-procedure contrast-enhanced magnetic resonance imaging. By enabling accurate diagnosis and treatment of MVO, CorFlow aims to reduce both short- and long-term complications in heart attack patients, addressing significant unmet medical needs in cardiovascular care.

SamanTree Medical SA is a Swiss company specializing in the development of innovative medical microscopy devices aimed at enhancing cancer treatment and surgical outcomes. Founded in 2014 and based in Ecublens, the company focuses on micro-optics-based digital microscopy systems that provide an extensive field of view for various applications, including research, diagnostics, and surgery. Its flagship product, a surgical digital microscope, enables real-time visualization of cellular structures within living tissue, facilitating precise assessment of tumor margins. This technology allows surgeons to achieve full margin control and make informed decisions during procedures, ultimately improving resection accuracy, reducing re-operation rates, and decreasing overall procedure costs. By enabling immediate visualization of cancerous cells during surgery, SamanTree Medical's devices significantly enhance patient care and outcomes in cancer surgery.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Enterprise Therapeutics, established in 2014 and headquartered in Brighton, UK, is a drug discovery company focused on developing therapies for respiratory diseases. Its primary focus is on chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company aims to create novel treatments that target the underlying mechanisms of mucus congestion, reducing lung infections and enhancing patients' quality of life.

DISCO Pharmaceuticals is a company focused on advancing cancer treatment through its innovative surfaceome mapping platform. This technology enables the identification of proteins and protein communities on the cancer cell surface at a large scale, providing detailed insights that traditional proteomics and genomic methods cannot offer. By unlocking the surfaceome of cancer cells, DISCO Pharmaceuticals aims to facilitate the development of cancer-selective therapies that enhance treatment efficacy while minimizing side effects for patients. The company's approach holds promise for improving patient care by enabling more targeted and effective therapeutic options in oncology.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Allotex, Inc. is an ophthalmic biologics and device company based in Boston, Massachusetts, established in 2013. The company specializes in developing innovative contact lenses and therapeutic solutions aimed at addressing refractive vision issues, including presbyopia, hyperopia, and myopia. Allotex utilizes precisely-shaped human corneal allografts in conjunction with a compact excimer laser system to create permanent, living contact lenses or lens inserts. This approach enables medical professionals to provide minimally invasive treatment options for various refractive procedures, enhancing patient outcomes in vision correction.

CarThera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices aimed at treating brain disorders. The company has created the SonoCloud®, an intracranial ultrasound implant that works in conjunction with a microbubble agent administered intravenously. This combination temporarily opens the blood-brain barrier, allowing for a significantly increased concentration of therapeutic molecules to penetrate the brain. By enhancing the delivery of treatments, CarThera's technology offers potential solutions for debilitating neurological conditions, providing healthcare professionals with new avenues for patient care.

EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

Complement Therapeutics is a preclinical stage biotechnology company focused on developing a precision medicine diagnostic platform to address chronic diseases associated with the dysregulation of the complement system. The company's innovative platform enables the stratification of patients based on their complement-activation profiles, which has the potential to enhance patient selection for clinical trials and serve as an efficacy biomarker in future studies. By offering a more tailored approach to treatment, Complement Therapeutics aims to improve medical outcomes for patients suffering from these chronic conditions.

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's flagship product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system, aiming to significantly reduce the suffering of patients affected by this condition, which impacts approximately 10% of the global adult population. Neuromod's patented technology is also being evaluated for other neurological disorders, with a commitment to empowering patients and integrating treatments seamlessly into modern lifestyles.

Approxima is an early-stage MedTech startup focused on developing a percutaneous method for tricuspid valve replacement. The company is working on a minimally invasive system designed to treat patients with tricuspid valve regurgitation by reshaping the right ventricle to counteract right heart dilation. This innovative approach enables medical professionals to implant the device using minimally invasive procedures guided by imaging techniques while the heart is still beating. Currently, Approxima is demonstrating in vivo safety, efficacy, and feasibility through preclinical trials.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

BetaGlue Technologies SpA specializes in the development and manufacture of medical devices designed for loco-regional radiation therapy targeting unresectable solid tumors. The company's innovative product utilizes a proprietary beta-emitting bio-compatible matrix, facilitating the controlled administration of radionuclides directly into tumor masses. This technology not only aims to enhance treatment efficacy but also plays a crucial role in preventing complications that may arise from procedures such as lung and liver biopsies and other localized treatments. Headquartered in Milan, Italy, BetaGlue Technologies is focused on advancing therapeutic options in the field of oncology.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, specializing in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures in the fields of cardiology, interventional radiology, and vascular surgery. Its primary product is a large-bore percutaneous closure device that employs an absorbable patch to effectively close large arteriotomies following transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical is dedicated to advancing medical solutions that enhance patient outcomes in vascular access procedures.

Diadem is a biotechnology company that focuses on developing a diagnostic platform to predict Alzheimer's disease. Utilizing a proprietary blood-based test, the company targets a specific conformation of the p53 protein through a unique antibody. This innovative approach allows for early predictions, monitoring, and diagnosis of Alzheimer's, ultimately facilitating more effective drug development. By providing accurate and timely information, Diadem aims to enhance the treatment options available for Alzheimer's patients while ensuring that these solutions are cost-effective.

InnovHeart is a medical equipment manufacturing company that specializes in developing transcatheter mitral valve replacement systems. The company focuses on creating innovative implant technologies designed to treat patients with mitral valve disease. Its products aim to provide a safe, effective, and user-friendly solution for replacing incompetent mitral valves, allowing hospitals to address heart valve dysfunction more efficiently.

Alesi Surgical Ltd. specializes in the development and commercialization of laparoscopic surgical smoke handling systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2009 and based in Cardiff, United Kingdom, the company emerged as a spin-out from the Welsh Institute for Minimal Access Therapy, benefiting from direct access to experienced surgeons and surgical trainers. Alesi Surgical's innovative products are designed to be portable and applicable in both laparoscopic and robot-assisted surgeries. Utilizing electrostatic precipitation technology, these tools effectively eliminate surgical smoke, ensuring a clear visual field during procedures. Alesi Surgical distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia.

Endostart is a developer of innovative colonoscopy technologies aimed at improving the efficiency and safety of colonoscopy procedures. The company has created a proprietary Magnetic Balloon Anchoring Technology, which includes a magnetic balloon guide, a ferrofluid syringe, and a multi-use magnetic handpiece. These advancements are designed to assist healthcare professionals in guiding and navigating colonoscopy procedures, thereby reducing wall stress and minimizing the need for general anesthesia. Through its unique approach, Endostart seeks to enhance patient comfort and streamline the colonoscopy process.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

InnovHeart is a medical equipment manufacturing company that specializes in developing transcatheter mitral valve replacement systems. The company focuses on creating innovative implant technologies designed to treat patients with mitral valve disease. Its products aim to provide a safe, effective, and user-friendly solution for replacing incompetent mitral valves, allowing hospitals to address heart valve dysfunction more efficiently.

SamanTree Medical SA is a Swiss company specializing in the development of innovative medical microscopy devices aimed at enhancing cancer treatment and surgical outcomes. Founded in 2014 and based in Ecublens, the company focuses on micro-optics-based digital microscopy systems that provide an extensive field of view for various applications, including research, diagnostics, and surgery. Its flagship product, a surgical digital microscope, enables real-time visualization of cellular structures within living tissue, facilitating precise assessment of tumor margins. This technology allows surgeons to achieve full margin control and make informed decisions during procedures, ultimately improving resection accuracy, reducing re-operation rates, and decreasing overall procedure costs. By enabling immediate visualization of cancerous cells during surgery, SamanTree Medical's devices significantly enhance patient care and outcomes in cancer surgery.

Endostart is a developer of innovative colonoscopy technologies aimed at improving the efficiency and safety of colonoscopy procedures. The company has created a proprietary Magnetic Balloon Anchoring Technology, which includes a magnetic balloon guide, a ferrofluid syringe, and a multi-use magnetic handpiece. These advancements are designed to assist healthcare professionals in guiding and navigating colonoscopy procedures, thereby reducing wall stress and minimizing the need for general anesthesia. Through its unique approach, Endostart seeks to enhance patient comfort and streamline the colonoscopy process.

CarThera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices aimed at treating brain disorders. The company has created the SonoCloud®, an intracranial ultrasound implant that works in conjunction with a microbubble agent administered intravenously. This combination temporarily opens the blood-brain barrier, allowing for a significantly increased concentration of therapeutic molecules to penetrate the brain. By enhancing the delivery of treatments, CarThera's technology offers potential solutions for debilitating neurological conditions, providing healthcare professionals with new avenues for patient care.

Aileens Pharma is engaged in the development of non-steroidal medications aimed at treating atopic dermatitis and other skin disorders. The company focuses on addressing the gap in non-pharmacological therapies for conditions such as atopic dermatitis, seborrheic dermatitis, and psoriasis. By creating topical treatments for both children and adults, Aileens Pharma seeks to provide effective solutions for healthcare providers in managing the symptoms associated with these dermatological issues. The company is currently working to accelerate the development of its treatment platform with the goal of enhancing therapeutic options available for patients suffering from various skin diseases.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Alesi Surgical Ltd. specializes in the development and commercialization of laparoscopic surgical smoke handling systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2009 and based in Cardiff, United Kingdom, the company emerged as a spin-out from the Welsh Institute for Minimal Access Therapy, benefiting from direct access to experienced surgeons and surgical trainers. Alesi Surgical's innovative products are designed to be portable and applicable in both laparoscopic and robot-assisted surgeries. Utilizing electrostatic precipitation technology, these tools effectively eliminate surgical smoke, ensuring a clear visual field during procedures. Alesi Surgical distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, specializing in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures in the fields of cardiology, interventional radiology, and vascular surgery. Its primary product is a large-bore percutaneous closure device that employs an absorbable patch to effectively close large arteriotomies following transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical is dedicated to advancing medical solutions that enhance patient outcomes in vascular access procedures.

Seventeen is a medtech startup. The company intends to use the funds to finalize the technology and clinically validate it in order to obtain the CE mark.

Echolight is an innovative biomedical company that has created the first radiation-free and office-based solution for assessing bone health. This non-invasive technology enables the early diagnosis and monitoring of osteoporosis, aiming to enhance the accuracy and accessibility of bone health assessments for both clinicians and patients. By focusing on early detection, Echolight addresses a critical need in the management of osteoporosis, which is essential for improving patient outcomes and overall bone health.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.